Biomerica Valuation Multiples

Discover revenue and EBITDA valuation multiples for Biomerica and similar public comparables like Bluejay Diagnostics, Centogene, Virax Biolabs Group, NRGene and more.

Biomerica Overview

About Biomerica

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.


Founded

1971

HQ

United States

Employees

54

Financials (FY)

Revenue: $5M
EBITDA: ($5M)

EV

$4M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Biomerica Financials

Biomerica reported last fiscal year revenue of $5M and negative EBITDA of ($5M).

In the same fiscal year, Biomerica generated $498K in gross profit, ($5M) in EBITDA losses, and had net loss of ($5M).


Biomerica P&L

In the most recent fiscal year, Biomerica reported revenue of $5M and EBITDA of ($5M).

Biomerica is unprofitable as of last fiscal year, with gross margin of 9%, EBITDA margin of (89%), and net margin of (94%).

See analyst estimates for Biomerica
Last FY202320242025202620272028
Revenue$5M$5M$5M$5M
Gross Profit$498K$542K$545K$498K
Gross Margin9%10%10%9%
EBITDA($5M)($6M)($5M)($5M)
EBITDA Margin(89%)(118%)(98%)(89%)
EBIT Margin(97%)(125%)(106%)(97%)
Net Profit($5M)($6M)($5M)($5M)
Net Margin(94%)(120%)(101%)(94%)
Net Debt($2M)---

Financial data powered by Morningstar, Inc.

Biomerica Stock Performance

Biomerica has current market cap of $5M, and enterprise value of $4M.

Market Cap Evolution


Biomerica's stock price is $1.52.

Biomerica has an EPS (earnings per share) of $-1.61.

See more trading valuation data for Biomerica
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4M$5M-1.9%---$-1.61

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Biomerica Valuation Multiples

Biomerica trades at 0.7x EV/Revenue multiple, and (0.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Biomerica

Biomerica Financial Valuation Multiples

As of August 21, 2026, Biomerica has market cap of $5M and EV of $4M.

Biomerica has a P/E ratio of (0.9x).

Last FY202320242025202620272028
EV/Revenue0.7x0.7x0.7x0.7x
EV/EBITDA(0.8x)(0.6x)(0.7x)(0.8x)
EV/EBIT(0.7x)(0.5x)(0.6x)(0.7x)
EV/Gross Profit7.1x6.6x6.5x7.1x
P/E(0.9x)(0.7x)(0.9x)(0.9x)
EV/FCF(0.9x)(0.6x)(0.8x)(0.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Biomerica Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Biomerica Margins & Growth Rates

In the most recent fiscal year, Biomerica reported gross margin of 9%, EBITDA margin of (89%), and net margin of (94%).

See estimated margins and future growth rates for Biomerica

Biomerica Margins

Last FY20242025202720282029
Gross Margin9%10%9%
EBITDA Margin(89%)(98%)(89%)
EBIT Margin(97%)(106%)(97%)
Net Margin(94%)(101%)(94%)
FCF Margin(73%)(85%)(73%)

Biomerica Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(1%)(1%)
Gross Profit Growth1%(9%)
EBITDA Growth(17%)(10%)
EBIT Growth(16%)(9%)
Net Profit Growth(17%)(8%)
FCF Growth(17%)(15%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Biomerica Operational KPIs

Biomerica's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Access forward-looking KPIs for Biomerica
Last FY202320242025202620272028
Revenue per Employee$0.1M---
Opex per Employee$0.1M---
R&D Expenses to Revenue19%28%23%19%
Opex to Revenue106%135%116%106%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Biomerica Competitors

Biomerica competitors include Bluejay Diagnostics, Centogene, Virax Biolabs Group, NRGene, Diagonal Bio, Lifeline Biotechnologies, Ludwig Enterprises, Integragen, 2cureX and Curative Biotechnology.

Most Biomerica public comparables operate across Diagnostics & Genomics, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Bluejay Diagnostics--0.8x-
Centogene0.1x-(0.1x)-
Virax Biolabs Group(300.5x)-0.7x-
NRGene0.6x-(2.0x)-
Diagonal Bio----
Lifeline Biotechnologies----
Ludwig Enterprises--(3.2x)-
Integragen(0.0x)-0.7x-

This data is available for Pro users. Sign up to see all Biomerica competitors and their valuation data.

Start Free Trial

Biomerica VC Funding History

Before going public, Biomerica raised $2M in total equity funding, across 1 round.


Biomerica Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Feb-20Seed-$2M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Biomerica

When was Biomerica founded?Biomerica was founded in 1971.
Where is Biomerica headquartered?Biomerica is headquartered in United States.
How many employees does Biomerica have?As of today, Biomerica has over 54 employees.
Is Biomerica publicly listed?Yes, Biomerica is a public company listed on Nasdaq.
What is the stock symbol of Biomerica?Biomerica trades under BMRA ticker.
Who are competitors of Biomerica?Biomerica main competitors include Bluejay Diagnostics, Centogene, Virax Biolabs Group, NRGene, Diagonal Bio, Lifeline Biotechnologies, Ludwig Enterprises, Integragen, 2cureX, Curative Biotechnology.
What is the current market cap of Biomerica?Biomerica's current market cap is $5M.
What is the current revenue of Biomerica?Biomerica's last fiscal year revenue is $5M.
What is the current EV/Revenue multiple of Biomerica?Current revenue multiple of Biomerica is 0.7x.
Is Biomerica profitable?No, Biomerica is not profitable.
How many companies Biomerica has acquired to date?Biomerica hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Biomerica has invested to date?Biomerica hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Biomerica

Lists including Biomerica

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial